Actualités

Greg Abel—CEO and top stock picker—reduced the company’s portfolio in financial shares during the second quarter.

DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...

DaVita HealthCare Partners Inc. (NYSE:DVA) shares gained around 2.

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

Xeltis recently secured an additional €20.5 million in funding led by Horizon 3 Healthcare, with DaVita participating to help advance the aXess™ vascular access platform through US trials, regulatory submissions, and European rollout. Alongside this investment, investor attention has intensified around DaVita’s upcoming August 2026 earnings report and its initiatives to expand equitable access to kidney care, including home dialysis and transplant support. With DaVita’s recent returns in...

Is DVA a good stock to buy? We came across a bullish thesis on DaVita Inc. on StockCompass’s Substack. In this article, we will summarize the bulls’ thesis on DVA. DaVita Inc.’s share was trading at $228.03 as of July 1st. DVA’s trailing and forward P/E were 21.43 and 15.34 respectively according to Yahoo Finance. DaVita Inc. […]

ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Pennant Group (PNTG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.

LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24th, 2026.

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.

ECPG, DK and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 17, 2026.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 17, 2026.

One dominates kidney care with global reach, while the other leads in rehab with faster growth and higher margins. Which business model stands out for 2026?

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 15, 2026.

For investors wondering whether DaVita at around US$208.66 is offering fair value or trading at a stretched price, this article walks through what the numbers are really saying about the stock. The stock has returned 8.6% over the past week, 4.5% over the last month, 82.2% year to date and 53.3% over the past year, which has put its recent performance firmly on investors' radar. Recent attention around DaVita has largely centred on its role in the US healthcare sector and on how the market...

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

PRTH, DVA and BFH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 11, 2026.

DVA, HRB, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 11, 2026.

DVA, XPO, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 9, 2026.

THG, DVA and PLOW made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 9, 2026.

DaVita (DVA) is back in focus after first quarter 2026 revenue and earnings surpassed analysts' expectations, prompting management to lift full year guidance and drawing fresh attention from investors and research desks. See our latest analysis for DaVita. The strong first quarter has come after a powerful run in the stock, with the share price up 27.46% over 90 days and a 67.81% year to date share price return. The 3 year total shareholder return of 97.13% suggests longer term holders have...

HRB, DVA and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 4th, 2026.

HRB, DVA and LCUT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 2nd, 2026.

CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.

LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.